XENETIC BIOSCIENCES, INC. Finance Lease, Right-of-Use Asset, Amortization
XENETIC BIOSCIENCES, INC. (XBIO) reported Finance Lease, Right-of-Use Asset, Amortization of $16.63 thousand for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2019-11-14
- XENETIC BIOSCIENCES, INC. finance lease, right-of-use asset, amortization for the quarter ending 2019-09-30 was $6.45K.
- XENETIC BIOSCIENCES, INC. finance lease, right-of-use asset, amortization for the quarter ending 2018-09-30 was $0.00.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month |
|---|---|---|---|
| 2019-09-30 | $6.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $16.63K 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $10.18K 10-Q · filed 2019-08-14 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $0.00 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |